Trial · NCT07045701
FMXIN002 in Patients at Risk of Anaphylaxis
NCT07045701, Phase 2, Phase 3, Enrolling by invitation, Nasus Pharma
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. FMXIN002 in Patients at Risk of Anaphylaxis. Trials, record NCT07045701. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07045701
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- FMXIN002 in Patients at Risk of Anaphylaxis
- NCT number
- NCT07045701
- Status
- Enrolling by invitation
- Phases
- Phase 2, Phase 3
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Nasus Pharma
- Conditions
- Anaphylaxis Food
- Interventions
- Epinephrine 4mg nasal powder spray, Adrenalin 0.5mg Injectable Product
- First posted
- 2025-07-01
- Last updated
- 2025-07-01
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Skin system anaphylaxis symptoms | 0-90 minutes after drug administration | Severity grading system for acute allergic reactions. Skin system, severity score 0 (=no reaction) to 5(= severe reaction), based on the Delphi study, 2021 |
| Primary | Mucosal system anaphylaxis symptoms | 0-90 minutes after drug administration | Severity grading system for acute allergic reactions, mucosal system, severity score 0 (=no reaction) to 5(= severe reaction), based on the Delphi study, 2021 |
| Primary | Gastrointestinal system anaphylaxis symptoms | 0-90 minutes after drug administration | Severity grading system for acute allergic reactions, gastrointestinal system, severity score 0 (=no reaction) to 5(= severe reaction), based on the Delphi study, 2021. |
| Primary | Respiratory system anaphylaxis symptoms | 0-90 minutes after drug administration | Severity grading system for acute allergic reactions, respiratory system, severity score 0 (=no reaction) to 5(= severe reaction), based on the Delphi study, 2021. |
| Primary | Total anaphylaxis severity score | 0-90 minutes after drug administration | Severity grading system for acute allergic reactions, Combined systems, anaphylaxis score 0 (=no reaction) to 5(= severe reaction), based on the Delphi study, 2021. |
| Primary | Vital signs: Blood pressure | 0-90 minutes after drug administration | Systolic and diastolic blood pressure by a blood pressure cuff |
| Primary | Vital signs: pulse rate | 0-90 minutes after drug administration | heart rate by pulse rate measurement |
| Primary | Vital signs: oxygen saturation | 0-90 minutes after drug administration | % oxygen saturation measurement using oxygen monitor |
| Secondary | Need for a second epinephrine dose | 0-90 minutes after drug administration | Number of patients needed a second dose, by Adrenalin IM injection |
| Secondary | Adverse events | 0-90 minutes after drug administration | Any treatment-related adverse events |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07045701
GET https://conductscience.org/api/trials/v1/NCT07045701/registered